Isavuconazole is preferred over voriconazole in invasive mucormycosis combined with invasive aspergillosis because:

• A Voriconazole is a stronger CYP3A4 inhibitor than isavuconazole, making comedication management difficult
• B Isavuconazole has activity against Mucorales (Rhizopus, Mucor) by inhibiting their ergosterol synthesis, while voriconazole is intrinsically inactive against all Mucorales ✓
• C Isavuconazole has better oral bioavailability and no cyclodextrin vehicle-related nephrotoxicity
• D Isavuconazole provides broader mold coverage including Fusarium species, unlike voriconazole which is Aspergillus-specific

Explanation

Voriconazole is intrinsically inactive against Mucorales (Rhizopus, Mucor, Lichtheimia, Cunninghamella) — a critically important clinical point, as breakthrough mucormycosis is documented in voriconazole-treated patients. Isavuconazole (a triazole targeting Cyp51 of fungi — the 14-alpha demethylase) has demonstrated in vitro and clinical activity against Mucorales, making it the only azole with efficacy in mucormycosis and aspergillosis. VITAL study established isavuconazole for mucormycosis. Both isavuconazole and voriconazole inhibit CYP enzymes; liposomal amphotericin B remains standard of care for mucormycosis but isavuconazole is a step-down/combination option.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.